PRIMARY IMMUNE THROMBOCYTOPENIA
Clinical trials for PRIMARY IMMUNE THROMBOCYTOPENIA explained in plain language.
Never miss a new study
Get alerted when new PRIMARY IMMUNE THROMBOCYTOPENIA trials appear
Sign up with your email to follow new studies for PRIMARY IMMUNE THROMBOCYTOPENIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Second chance: drug retrial for patients whose blood disorder came back
Disease control Recruiting nowThis study is for adults with two specific blood disorders (ITP and wAIHA) who previously benefited from the drug ianalumab but later saw their condition worsen. It aims to see if giving a second course of the same drug is safe and effective at controlling the disease again. The …
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
Last-Hope drug access opens for rare immune diseases
Disease control AVAILABLEThis is a special access program, not a traditional clinical trial. It provides the experimental drug ianalumab (VAY736) to patients with serious immune conditions like Primary Immune Thrombocytopenia (ITP) and Sjögren's Syndrome. The program is for patients who have no other tre…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New injection aims to boost platelets in blood disorder patients
Disease control Recruiting nowThis study is testing whether a new injectable medication called PF-06835375 can safely increase platelet counts in adults with moderate to severe immune thrombocytopenia (ITP). Participants will receive monthly injections for 3-4 months while researchers monitor their platelet l…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA
Phase: PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Mar 16, 2026 15:25 UTC
-
Major study launches to map the future for kids with rare bleeding disorder
Knowledge-focused Recruiting nowThis study aims to learn more about a rare childhood bleeding disorder called immune thrombocytopenia (ITP). Researchers will follow 500 children in China diagnosed with ITP to observe their symptoms, treatments, and long-term health. The goal is to identify patterns that can hel…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA
Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:41 UTC